Zhuang Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhuang Han has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Pei-Yuan Qian
Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou), Guangzhou 511458, China
3 shared publications - Ying Xu
Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China
3 shared publications - Yong-Xin Li
Department of Chemistry and The Swire Institute of Marine Science, The University of Hong Kong
3 shared publications - Lingli Liu
Division of Life Science, the Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
2 shared publications - Xian-Rong Guo
Imaging and Characterization Core Lab, King Abdullah University of Science and Technology, 127355 Thuwal, Mecca Saudi Arabia
2 shared publications - Xixiang Zhang
Physical Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia
2 shared publications
Latest Publications
- Open Access
- 20 November 2012
- Published by MDPI AG in Marine Drugs
- Vol. 10 (11) , 2571-2583
Four New Antibacterial Xanthones from the Marine-Derived Actinomycetes Streptomyces caelestis
Four new polycyclic antibiotics, citreamicin θ A (1), citreamicin θ B (2), citreaglycon A (3), and dehydrocitreaglycon A (4), were isolated from marine-derived Streptomyces caelestis. The structures of these compounds were elucidated by 1D and 2D NMR spectra. All four compounds displayed antibacterial activity against Staphylococcus haemolyticus, Staphylococcus aureus, and Bacillus subtillis. Citreamicin θ A (1), citreamicin θ B (2) and citreaglycon A (3) also exhibited low MIC values of 0.25, 0.25, and 8.0 μg/mL, respectively, against methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300.
- 20 November 2012
- Published by MDPI AG in Marine Drugs
- Vol. 10 (11) , 2571-2583
Open AccessFour New Antibacterial Xanthones from the Marine-Derived Actinomycetes Streptomyces caelestis
Four new polycyclic antibiotics, citreamicin θ A (1), citreamicin θ B (2), citreaglycon A (3), and dehydrocitreaglycon A (4), were isolated from marine-derived Streptomyces caelestis. The structures of these compounds were elucidated by 1D and 2D NMR spectra. All four compounds displayed antibacterial activity against Staphylococcus haemolyticus, Staphylococcus aureus, and Bacillus subtillis. Citreamicin θ A (1), citreamicin θ B (2) and citreaglycon A (3) also exhibited low MIC values of 0.25, 0.25, and 8.0 μg/mL, respectively, against methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300.
- Open Access
- 22 March 2012
- Published by MDPI AG in Marine Drugs
- Vol. 10 (3) , 668-676
Two Antimycin A Analogues from Marine-Derived Actinomycete Streptomyces lusitanus
Two new antimycin A analogues, antimycin B1 and B2 (1–2), were isolated from a spent broth of a marine-derived bacterium, Streptomyces lusitanus. The structures of 1 and 2 were established on the basis of spectroscopic analyses and chemical methods. The isolated compounds were tested for their anti-bacterial potency. Compound 1 was found to be inactive against the bacteria Bacillus subtilis, Staphyloccocus aureus, and Loktanella hongkongensis. Compound 2 showed antibacterial activities against S. aureus and L. hongkongensis with MIC values of 32.0 and 8.0 μg/mL, respectively.
- 22 March 2012
- Published by MDPI AG in Marine Drugs
- Vol. 10 (3) , 668-676
Open AccessTwo Antimycin A Analogues from Marine-Derived Actinomycete Streptomyces lusitanus
Two new antimycin A analogues, antimycin B1 and B2 (1–2), were isolated from a spent broth of a marine-derived bacterium, Streptomyces lusitanus. The structures of 1 and 2 were established on the basis of spectroscopic analyses and chemical methods. The isolated compounds were tested for their anti-bacterial potency. Compound 1 was found to be inactive against the bacteria Bacillus subtilis, Staphyloccocus aureus, and Loktanella hongkongensis. Compound 2 showed antibacterial activities against S. aureus and L. hongkongensis with MIC values of 32.0 and 8.0 μg/mL, respectively.
- Open Access
- 3 February 2012
- Published by MDPI AG in Marine Drugs
- Vol. 10 (2) , 319-328
Five New Amicoumacins Isolated from a Marine-Derived Bacterium Bacillus subtilis
Four novel amicoumacins, namely lipoamicoumacins A–D (1–4), and one new bacilosarcin analog (5) were isolated from culture broth of a marine-derived bacterium Bacillus subtilis, together with six known amicoumacins. Their structures were elucidated on the basis of extensive spectroscopic (2D NNR, IR, CD and MS) analysis and in comparison with data in literature.
- 3 February 2012
- Published by MDPI AG in Marine Drugs
- Vol. 10 (2) , 319-328
Open AccessFive New Amicoumacins Isolated from a Marine-Derived Bacterium Bacillus subtilis
Four novel amicoumacins, namely lipoamicoumacins A–D (1–4), and one new bacilosarcin analog (5) were isolated from culture broth of a marine-derived bacterium Bacillus subtilis, together with six known amicoumacins. Their structures were elucidated on the basis of extensive spectroscopic (2D NNR, IR, CD and MS) analysis and in comparison with data in literature.